ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, announced that Mark Enyedy, President and CEO, will present at the upcoming 35th Annual J. P. Morgan Healthcare Conference in San Francisco. The presentation is scheduled for 2:30 pm PT (5:30 pm ET) on January 11, 2017.
Following the presentation, Mr. Enyedy will be joined by other members of ImmunoGen’s management team for a question-and-answer session at 3:00 pm PT (6:00 pm ET).
A webcast of the presentation and question-and-answer session will be accessible live through the "Investors" section of the Company's website, www.immunogen.com; a replay will be available at the same location for approximately a week.
About ImmunoGen
ImmunoGen is a clinical-stage biotechnology
company that develops targeted cancer therapeutics using its proprietary
ADC technology. ImmunoGen’s lead product candidate, mirvetuximab
soravtansine, is in a Phase 3 trial for FRα-positive platinum-resistant
ovarian cancer, and is in Phase 1b/2 testing in combination regimens for
earlier-stage disease. ImmunoGen’s ADC technology is used in Roche's
marketed product, Kadcyla®, in three other clinical-stage
ImmunoGen product candidates, and in programs in development by partners
Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda. More
information about the Company can be found at www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of the Roche Group.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161228005025/en/
Contacts:
Investor Contact:
Sarah Kiely,
781-895-0600
sarah.kiely@immunogen.com
or
Media
Contacts:
Amy Reilly, 781-895-0138
amy.reilly@immunogen.com
or
FTI
Consulting, Inc.
Robert Stanislaro, 212-850-5657
robert.stanislaro@fticonsulting.com